Breathe BioMedical Inc. (BRTH)
Breathe BioMedical was planning to go public, but the IPO was withdrawn on Oct 28, 2024.
IPO Price Range
$4.00 - $6.00
Shares Offered
2,625,000
Deal Size
$13.13M

Company Description

Breathe BioMedical is a medical technology company focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue.

Breathe BioMedical is in the development stage of our Breast Cancer Breath Test. Over the next two years we have verification and validation studies planned for the components and the Breast Cancer Breath Test, as well as a large multi-center clinical study planned to evaluate the safety and efficacy of the Breast Cancer Breath Test, subject to discussions with regulatory authorities, and build our machine learning model for breast cancer.

We are currently conducting a proof-of-concept study. Data collection will be completed in 3Q2024.

Breathe BioMedical Inc.
CountryCanada
Founded2005
IndustryMedical Devices
SectorHealthcare
Employees26
CEOWilliam Dawes

Contact Details

Address:
191 Halifax Street
Moncton, NB E1C 9R6
Canada
Phone(506) 855-2400
Websitebreathebiomedical.com

Stock Details

Ticker SymbolBRTH
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyCAD
CIK Code0002004349
SIC Code3841

Key Executives

NamePosition
William DawesChief Executive Officer
Sandra VeenstraChief Regulatory Officer
Peili MiaoChief Financial Officer
Christopher PurvesChief Technology Officer
Dr. Rachel BremChief Medical Officer and Director
Joanne YoungVice President, Clinical
Jean NadeauChairman of the Board
Telfer HansonVice Chairman of the Board
Dr. Norman BettsDirector
Romeo GoguenDirector

Latest SEC Filings

DateTypeTitle
Oct 28, 2024RWFiling
Oct 10, 2024F-1/A[Amend] Registration statement for certain foreign private issuers
Oct 4, 2024FWPFree Writing Prospectus
Sep 30, 2024F-1/A[Amend] Registration statement for certain foreign private issuers
Sep 16, 2024FWPFree Writing Prospectus
Sep 13, 2024F-1/A[Amend] Registration statement for certain foreign private issuers
Jul 30, 2024FWPFree Writing Prospectus
Jul 26, 2024F-1/A[Amend] Registration statement for certain foreign private issuers
Jul 26, 2024FWPFree Writing Prospectus
Jul 15, 2024FWPFree Writing Prospectus